11.03.14
Daniel H. Rosenbaum has been appointed as chief operating officer of NattoPharma USA, Inc., Metuchen, NJ.
“The employment of Daniel H. Rosenbaum reflects a shift in our company and points to the opportunity for a significant growth of the science-backed vitamin K2 market for MenaQ7,” commented Frode M. Bohan, chairman of NattoPharma ASA, Høvik, Norway. “Rosenbaum has a strong network within the omega-3 and dietary supplement industry. This, in combination with the increasing business potential for MenaQ7 in the U.S., reinforces NattoPharma’s great expectations for the future.”
Prior to joining NattoPharma, Mr. Rosenbaum served as general manager of Nutraceuticals of FMC Health & Nutrition, a division of the Philadelphia, PA-based FMC Corporation, where he worked in various leadership capacities starting in 1995. Most recently at FMC Health & Nutrition, he led the integration of the $345-million acquisition of a premium omega-3 producer, with operations in Norway and UK.
Mr. Rosenbaum's role will help drive and realize the next commercial phase of NattoPharma and its signature ingredient, MenaQ7, and to add strategic capabilities to enable further business growth.
“The employment of Daniel H. Rosenbaum reflects a shift in our company and points to the opportunity for a significant growth of the science-backed vitamin K2 market for MenaQ7,” commented Frode M. Bohan, chairman of NattoPharma ASA, Høvik, Norway. “Rosenbaum has a strong network within the omega-3 and dietary supplement industry. This, in combination with the increasing business potential for MenaQ7 in the U.S., reinforces NattoPharma’s great expectations for the future.”
Prior to joining NattoPharma, Mr. Rosenbaum served as general manager of Nutraceuticals of FMC Health & Nutrition, a division of the Philadelphia, PA-based FMC Corporation, where he worked in various leadership capacities starting in 1995. Most recently at FMC Health & Nutrition, he led the integration of the $345-million acquisition of a premium omega-3 producer, with operations in Norway and UK.
Mr. Rosenbaum's role will help drive and realize the next commercial phase of NattoPharma and its signature ingredient, MenaQ7, and to add strategic capabilities to enable further business growth.
